Difficulty: Medium
Average Score: 95%
Practice
A 62-year-old retired small business owner has had slowly increasing intraocular pressure bilaterally. You start him on drug used to treat his open-angle glaucoma, which also happens to cross the blood├óÔé¼ÔÇ£brain barrier better than other drugs in its class. Which of the following drugs is this?
Correct answer
D
Rationale
The correct answer is D) Physostigmine. Physostigmine is a cholinesterase inhibitor that is used to treat open-angle glaucoma due to its ability to cross the blood-brain barrier more effectively compared to other drugs in its class. This property allows physostigmine to exert its pharmacological effects centrally as well as peripherally, making it a more potent option for treating conditions like glaucoma.
A) Echothiophate is also a cholinesterase inhibitor used in the treatment of glaucoma, but it does not cross the blood-brain barrier as effectively as physostigmine.
B) Edrophonium is a short-acting cholinesterase inhibitor primarily used for diagnostic purposes in conditions like myasthenia gravis, and it does not have the same blood-brain barrier penetration as physostigmine.
C) Neostigmine is another cholinesterase inhibitor commonly used to treat conditions like myasthenia gravis and postoperative urinary retention, but it does not have the same central nervous system effects as physostigmine.
In an educational context, understanding the pharmacokinetic properties of CNS drugs is crucial for healthcare professionals to make informed decisions when selecting appropriate treatments for patients. Knowledge of how different drugs interact with physiological barriers like the blood-brain barrier can impact treatment efficacy and potential side effects.
A) Echothiophate is also a cholinesterase inhibitor used in the treatment of glaucoma, but it does not cross the blood-brain barrier as effectively as physostigmine.
B) Edrophonium is a short-acting cholinesterase inhibitor primarily used for diagnostic purposes in conditions like myasthenia gravis, and it does not have the same blood-brain barrier penetration as physostigmine.
C) Neostigmine is another cholinesterase inhibitor commonly used to treat conditions like myasthenia gravis and postoperative urinary retention, but it does not have the same central nervous system effects as physostigmine.
In an educational context, understanding the pharmacokinetic properties of CNS drugs is crucial for healthcare professionals to make informed decisions when selecting appropriate treatments for patients. Knowledge of how different drugs interact with physiological barriers like the blood-brain barrier can impact treatment efficacy and potential side effects.